Company Profile
Dermapharm - Pharmaceutical Excellence
“Made in Germany”
Dermapharm is an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products. Founded in 1991, the Company is based in Grünwald near Munich. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Germany, the rest of Europe and the United States.
In the "Branded pharmaceuticals" segment, Dermapharm has more than 1,200 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals is tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany. The Company's integrated business model extends from in-house product development and production through quality management and logistics to the distribution of branded pharmaceuticals by a trained pharmaceutical sales force.
Dermapharm bundles food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts and medicinal cannabis in its "Other healthcare products" segment. In this segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries, and Arkopharma, the market leader for herbal medicines and food supplements in France.
Dermapharm also operates the "Parallel import business" segment under the axicorp brand. axicorp imports originator pharmaceuticals from other EU Member States and resells them to pharmaceuticals wholesalers and pharmacies in Germany. This enables axicorp to benefit from the different pricing structures in the individual EU member states. Based on revenue, axicorp is currently one of the top five parallel import companies in Germany.
With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, the Group is continuously optimising its business activities and seeks external growth opportunities in addition to organic growth.
WILHELM BEIER
Wilhelm Beier was born in Eicherscheid (Bad Münstereifel), Germany, on April 21, 1956. Starting his career in 1981, he held various positions in the pharmaceuticals industry, including a managing director of the German subsidiaries of an international pharmaceuticals manufacturer. After founding Dermapharm in 1991, Mr. Beier served as Chief Executive Officer of Dermapharm AG.
In 2017, he was appointed chairman of the supervisory board of Dermapharm.
Mr. Beier and his family hold the majority of the company's shares via Themis Beteiligungs AG.
DR. ERWIN KERN
Dr Erwin Kern was born on July 6, 1960 in Karlsruhe, Germany. In 1986, Dr. Kern completed his studies in business administration at the Ludwig Maximilian University in Munich. In 1989, he received his doctorate in economics from the University of Paderborn. Dr. Kern began his professional career in 1986 as Managing Director of HBK-Handel und Beteiligungen Kern GmbH & Co. KG. From 1991 onwards, he was a member of the management of Kies und Beton Baden-Baden GmbH & Co. Holding KG and Kies und Beton AG Baden-Baden. In 2007, Dr. Kern took over the chairmanship of the management of these companies, which he still holds today. Since 2003, he has been President of the Federal Association of the German Ready-Mixed Concrete Industry (BTB). (BTB) since 2003 and was Chairman from 2008 to 2011 and Vice Chairman from 2011 to 2013 of Construction Products Europe (CPE) (Association of European Construction Materials Manufacturers).
Dr Kern was appointed as a member of the Supervisory Board of Dermapharm Holding SE in 2017. In addition to his position at Dermapharm, Dr Kern was and is active in various companies and associations in the stone and earth industry that are not listed on the stock exchange.
LOTHAR LANZ
Lothar Lanz was born on October 1, 1948 in Bihlafingen, Germany. From 1969 to 1974, Mr. Lanz studied business administration at the universities of Stuttgart and Berlin and graduated with a degree in business administration. Mr. Lanz began his professional career as an audit assistant for an auditor and tax consultant in Berlin. In 1977, Mr. Lanz joined Bayerische Hypotheken- und Wechselbank AG, where he served as branch manager from 1983 to 1990. In 1991, Mr. Lanz became a member of the Board of Management of H.S.B. HYPO Service-Bank AG, Munich. In 1996, he moved to Nassauische Sparkasse, Wiesbaden, where he also became a member of the Board of Management. In the same year, Mr. Lanz moved to the then ProSieben Media AG (now ProSiebenSat.1 Media AG) as Chief Financial Officer, a post he held until 2008. From 2009 to 2014, Mr. Lanz was a member of the Executive Board of Axel Springer AG (now Axel Springer SE), where he served as Chief Financial and Operating Officer.
Mr. Lanz was appointed as a member of the Supervisory Board of Dermapharm Holding SE in 2017. In addition, he is currently Chairman of the Supervisory Board of Home 24 SE, a member of the Supervisory Board of TAG Immobilien AG and the unlisted Bauwert AG as well as Chairman of the Board of Directors of the unlisted SMG Swiss Marketplace Group AG. Until 2019, he was also a member of the Supervisory Board of Axel Springer SE and Chairman of the Supervisory Board of Zalando SE
Subsidiaries
Overview of subsidiaries
In the overview you will find our subsidiaries with focus on our company brands and groups within the Dermapharm Group. If required, further locations of these company brands abroad can be shown if available. The detailed organization chart of the Group structures and interests can be found on page 36 of the Annual Report 2021.
Branded pharmaceuticals
Montavit GmbH
[Translate to English:]
Die pharmazeutische Fabrik Montavit GmbH in Absam, Österreich, bietet Lösungen in den Therapiegebieten Atemwege, Erholung & Schlaf, Frauengesundheit, Harnwege, Haut & Allergie, Reiseapotheke, Verdauungssystem. Am 7. Juni 2023 hat Dermapharm wesentliche Anteil an der Montavit übernommen.
